Premium
1,25‐dihydroxycholecalciferol‐induced differentiation of myelomonocytic leukemic cells unresponsive to colony stimulating factors and phorbol esters
Author(s) -
Bettens Florence,
Schlick Erich,
Farrar William,
Ruscetti Francis
Publication year - 1986
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.1041290305
Subject(s) - haematopoiesis , cellular differentiation , cell culture , cholecalciferol , monocyte , receptor , biology , microbiology and biotechnology , phorbol , colony stimulating factor , endocrinology , medicine , vitamin , immunology , biochemistry , signal transduction , protein kinase c , stem cell , genetics , gene
The murine myelomonocytic leukemia cell line WEHI‐3B D + , which differentiates in response to granulocyte colony stimulating factor (G‐CSF), can also be induced to differentiate into monocyte‐macrophages by phorbol myristate acetate (PMA) treatment, whereas the WEHI‐3B D − subline, which is unresponsive to G‐CSF and PMA, can be induced to differentiate to granulocytes as well as monocytes by, 1, 25‐dihydroxycholecalciferol [1, 25‐(OH) 2 D3], the biologically active metabolite of vitamin D3. A newly developed variant of the WEHI‐3B D + line, named WEHI‐3B D + G, which was responsive to G‐CSF but not to PMA, was also differentiated to granulocytes by 1,25‐(OH) 2 D3. Although vitamin D3 has been reported to induce macrophage differentiation in responsive tumor cells, this is the first demonstration that 1,25‐(OH) 2 D3 can induce granulocyte differentiation. In both differentiation pathways, cessation of. cellular proliferation accompanies changes in morphologic and cytochemical properties of the cells. This suggests that leukemic cell lines unresponsive to differentiation agents acting at the cell surface retain their ability to differentiate in response to agents that do not act via the plasma membrane such as 1,25‐(OH) 2 D3, which has cytosolic/nuclear receptors. Vitamin D3 could act through different cellular pathways inducing differentiation or by bypassing only the first step of a common differentiation cascade used by agents with cell surface receptors such as CSF. These results suggest that low doses of 1,25‐(OH) 2 D3 may be useful in combination with hemopoietic growth factors (CSFs) as therapeutic agent to induce leukemic cell differentiation in vivo.